title: Cost-Analyses Studies in Barrett's Esophagus: What Is Their Utility?
abstract: Approximately 10% to 15% of the chronic gastroesophageal reflux disease population is at risk for the development of Barrett's esophagus, particularly in the setting of other risk factors, including male gender, Caucasian race, age more than 50, and central obesity. The risk of cancer progression for patients with nondysplastic BE has been estimated to be approximately 0.2% to 0.5% per year. Given these low progression rates and the high cost of endoscopic surveillance, cost-effectiveness analyses in this area are useful to determine appropriate resource allocation.
authors.affiliation: California Pacific Medical Center, 2340 Clay Street, 6th Floor, San Francisco, CA 94115, USA. Electronic address: GersonL@sutterhealth.org.
authors.forename: Lauren B
authors.initials: LB
authors.lastname: Gerson
mesh_terms: D001471:Barrett Esophagus / Q000175:diagnosis / Q000191:economics* / Q000517:prevention & control / Q000628:therapy*; D018890:Chemoprevention / Q000191:economics; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D004945:Esophagoscopy / Q000191:economics; D006801:Humans; D008403:Mass Screening / Q000191:economics*; D018803:Models, Economic; D011159:Population Surveillance; D019057:Quality-Adjusted Life Years; D012737:Sex Factors
keywords: Ablation therapy; Barrett’s esophagus; Cost-effectiveness; Health-state utilities; Markov model